2019 ANNUAL REPORT
Precision BioSciences Announces Closing of IPO
Duke start-up, Precision BioSciences, has closed its initial public offering of 9,085,000 shares of common stock at a public offering price of $16.00 per share, for total gross proceeds of approximately $145.4 million.
NEW START-UP: Gavilán Biodesign
An interdisciplinary team of Duke scientists, have developed a software platform that predicts and out-maneuvers possible drug resistance mutations. Using their proprietary AI technology to design drugs with a property called resistance-resilience, Gavilán has the potential to change the way drugs are made by introducing the ideas of evolution and time into drug design.
Duke’s 1st Venture Day
Over a dozen venture capital firms gathered for the first Duke Venture Day at the newly refurbished Chesterfield Building in downtown Durham
16
NEW START-UPS CREATED
This year we’ve helped grow and develop ventures ranging from CRISPR-based reagent kits to AI software
“Deep Sepsis” Licensed to Cohere Med
Cohere Med licenses technology from Duke to drive adoption of early Sepsis detection using AI
NEW START-UP:
Metacept Systems
Leveraging metamaterials for innovative electromagnetic systems
NEW START-UP:
CasTag Biosciences
Developing innovative CRISPR-based reagent kits for
labeling and manipulating endogenous proteins